Cannabis Import and Export Regulations in the EU

International trade in cannabis within and between EU member states is governed by a layered system of international conventions, EU regulations, and national licensing frameworks. At the international level, the 1961 UN Single Convention on Narcotic Drugs establishes the foundational requirement that all cross-border cannabis trade must be conducted under a system of import and export authorizations monitored by the International Narcotics Control Board (INCB). Each shipment of cannabis requires matching import and export permits issued by the competent authorities of both the importing and exporting countries. Within the EU, the single market framework does not override national controlled substance regulations for cannabis. Unlike most goods, cannabis does not benefit from free movement principles — each cross-border transaction requires country-specific permits regardless of whether it moves between EU member states or from a third country. The practical result is a complex permit-based trading system that adds significant time and cost to the cannabis supply chain. Major trade corridors for medical cannabis in Europe include imports from Canada, Denmark, Portugal, and the Netherlands into Germany (Europe's largest medical cannabis market), as well as growing intra-EU trade as more countries establish domestic medical cannabis programs.

The import and export permit system for cannabis derives from Articles 31 and 32 of the 1961 Single Convention. For each shipment, the importing country's competent authority issues an import permit specifying the substance, quantity, importer, and purpose. This permit is transmitted to the exporting country, whose competent authority then issues a matching export permit. The exporting country must verify that the import permit is genuine and that the import is authorized under the laws of the receiving country. Upon arrival, the importing country's customs and health authorities verify the shipment against the permits and issue a delivery confirmation that is returned to the exporting country. The INCB receives copies of all permits and monitors global cannabis trade flows to identify irregularities. This per-shipment permit system creates inherent lead times of 4-12 weeks from order to delivery, which companies must factor into their supply chain planning.

In practice, the major cannabis importing countries in Europe are Germany, Italy, the United Kingdom (pre- and post-Brexit), Poland, and the Czech Republic. Germany dominates European medical cannabis imports, having imported over 30 tonnes of medical cannabis in 2025 through companies including Tilray, Aurora, Canopy Growth (via C3 Cannabinoid Compound Company), and numerous smaller specialized importers. The import process in Germany involves obtaining an import permit from the BfArM (Federal Institute for Drugs and Medical Devices), ensuring the product meets German Pharmacopoeia quality standards, arranging transport through authorized logistics providers, clearing customs with presentation of permits and certificates of analysis, and release by a Qualified Person at the importing company's GDP/GMP-licensed facility. Products must be GMP-certified at the manufacturing site, and the manufacturer's GMP certificate must be valid and recognized by German authorities.

Exporting cannabis from EU member states involves mirror obligations. Major exporting countries include the Netherlands (through Bedrocan and its government cannabis program), Denmark (Tilray's EU production hub), Portugal (multiple licensed producers including Tilray, Aurora, and Somai Pharmaceuticals), and more recently Germany as it develops domestic production capacity. The exporting country's competent authority — such as the Danish Medicines Agency or Portugal's Infarmed — must verify that the destination country has issued a valid import permit before authorizing export. Companies must hold appropriate manufacturing and wholesale distribution authorizations, maintain GMP compliance for the products being exported, and arrange transport through qualified logistics providers who hold Good Distribution Practice (GDP) certification. Temperature-controlled transport is essential for cannabis products, and the entire cold chain must be validated and documented.

Emerging developments in EU cannabis trade include discussions about mutual recognition frameworks that could streamline intra-EU cannabis trade, the growing importance of EU-based cultivation to reduce dependence on non-EU imports, and the impact of expanding national medical cannabis programs on demand patterns. Israel, Australia, and several Latin American countries are also developing as export sources for the European market, though non-EU suppliers face additional regulatory hurdles including the need for EU GMP inspections of their facilities. The European cannabis trade landscape is expected to consolidate as regulatory frameworks mature, with larger operators who can manage the complexity of multi-country permit systems gaining advantage over smaller companies that lack the regulatory infrastructure to navigate international trade compliance.